Compare Amylx Pharmaceuticals Inc (AMLX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while ProShares UltraPro Short QQQ ETF trades at $38.7. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | SQQQ | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $18.70 | $97.60 |
52-Week Low | $7.64 | $36.31 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SQQQ trades at $37.78, down 0.84% on the day, with a bearish technical signal driven by moving averages. The ETF, designed to deliver -3x the daily return of the Nasdaq-100, faces structural decay from daily resets, evidenced by long-term value erosion. Recent news highlights its role as a tactical hedge rather than a long-term holding, with short interest rising 19.4% in March 2026 (Defense World, 2026-04-19).
Outlook remains highly speculative; SQQQ offers potential for short-term gains during Nasdaq declines but carries extreme risk from volatility decay. Investors must actively manage positions due to the ETF's unsuitability for buy-and-hold strategies, with success dependent on precise market timing amid bearish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
